Immunovant Inc (NASDAQ:IMVT)’s traded shares stood at 1.02 million during the latest session, with the company’s beta value hitting 0.62. At the last check today, the stock’s price was $16.03, to imply a decrease of -0.74% or -$0.12 in intraday trading. The IMVT share’s 52-week high remains $34.47, putting it -115.03% down since that peak but still an impressive 20.65% since price per share fell to its 52-week low of $12.72.

Analysts have given a consensus recommendation of Buy for Immunovant Inc (IMVT), translating to a mean rating of 1.33. Of 20 analyst(s) looking at the stock, 1 analyst(s) give IMVT a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 13 recommend it as a Buy.

Immunovant Inc (NASDAQ:IMVT) trade information

After registering a -0.74% downside in the latest session, Immunovant Inc (IMVT) has traded red over the past five days. The 5-day price performance for the stock is 0.06%, and 14.34% over 30 days. With these gigs, the year-to-date price performance is -35.28%.

The extremes give us $5 and $57 for target low and target high price respectively. As such, IMVT has been trading -255.58% off suggested target high and 68.81% from its likely low.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -12.18% for the past 5-year period. While 2025 is set for a -4.82% return in earnings, projections for the next 5 years are at -1.56% annually.

IMVT Dividends

Immunovant Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

The next major institution holding the largest number of shares is VANGUARD GROUP INC with 6.51 million shares, or about 4.4561% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $171.86 million.